A few interesting facts about drug company Gilead Sciences, Inc.:
- 81% of all treat HIV-positive individuals (US & European Union) receive a Gilead HIV drug;
- 90% of patients who are just starting HIV treatment (US & Europe Union) receive a Gilead drug.
- Gilead’s revenues topped $8 billion in revenues last year.
Isn’t it time for Gilead to stop holding AIDS care hostage & lower their prices?
State AIDS Drug Assistance Programs (ADAPs) continue to struggle – with more than 3,000 people nationwide still on waiting lists to receive lifesaving care.
Yet now, Gilead has a “new” drug known as the Quad, which is likely to hit the market later this year – with a price that could be 2 or 3 times higher than any other drug purchased by state ADAPs. Not only is the Quad NOT a significant improvement over Gilead’s Atripla—the most prescribed brand— it contains the same active ingredient – Truvada. Download this fact sheet for more information on QUAD and ADAP.
Join AIDS Healthcare Foundation and other advocates in telling Gilead to stop squeezing every last cent out of Truvada.
